General Information of the Compound
Compound ID |
CP0219552
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
1-N'-[3-fluoro-4-[6-[2-hydroxy-3-(4-hydroxypiperidin-1-yl)propoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C32H34F2N6O6
|
||||||||||||||||||
Molecular Weight |
636.656
|
||||||||||||||||||
Canonical SMILES |
Cc1c(OCC(O)CN2CCC(O)CC2)cn2ncnc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c12
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C32H34F2N6O6/c1-19-27(45-17-24(42)15-39-12-8-23(41)9-13-39)16-40-28(19)29(35-18-36-40)46-26-7-6-22(14-25(26)34)38-31(44)32(10-11-32)30(43)37-21-4-2-20(33)3-5-21/h2-7,14,16,18,23-24,41-42H,8-13,15,17H2,1H3,(H,37,43)(H,38,44)
Show/Hide
|
||||||||||||||||||
InChIKey |
VIIXGCDJLIQYIW-UHFFFAOYSA-N
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01201, Hepatocyte growth factor receptor
Cell Viability or Cytotoxicity Assay
Cell Line ID | Cell Line Name | Cell Line Organism | |
CL000246 | NCI-H292 | Homo sapiens (Human) | 1 |
1 |
IC50 >= 50 nM
|
TI
LI
LO
TS
|
|
---|---|---|---|
CL000749 | HUVEC-C | Homo sapiens (Human) | 1 |
1 |
IC50 = 47.9 nM
|
TI
LI
LO
TS
|